14-3-3-zeta mediates GLP-1 receptor agonist action to alter α cell proglucagon processing

MM Holter, DJ Phuong, I Lee, M Saikia, L Weikert… - Science …, 2022 - science.org
MM Holter, DJ Phuong, I Lee, M Saikia, L Weikert, S Fountain, ET Anderson, Q Fu, S Zhang
Science Advances, 2022science.org
Recent studies demonstrate that α cells contribute to glucose-stimulated insulin secretion
(GSIS). Glucagon-like peptide-1 receptor (GLP-1R) agonists potently potentiate GSIS,
making these drugs useful for diabetes treatment. However, the role of α and β cell paracrine
interactions in the effects of GLP-1R agonists is undefined. We previously found that
increased β cell GLP-1R signaling activates α cell GLP-1 expression. Here, we
characterized the bidirectional paracrine cross-talk by which α and β cells communicate to …
Recent studies demonstrate that α cells contribute to glucose-stimulated insulin secretion (GSIS). Glucagon-like peptide-1 receptor (GLP-1R) agonists potently potentiate GSIS, making these drugs useful for diabetes treatment. However, the role of α and β cell paracrine interactions in the effects of GLP-1R agonists is undefined. We previously found that increased β cell GLP-1R signaling activates α cell GLP-1 expression. Here, we characterized the bidirectional paracrine cross-talk by which α and β cells communicate to mediate the effects of the GLP-1R agonist, liraglutide. We find that the effect of liraglutide to enhance GSIS is blunted by α cell ablation in male mice. Furthermore, the effect of β cell GLP-1R signaling to activate α cell GLP-1 is mediated by a secreted protein factor that is regulated by the signaling protein, 14-3-3-zeta, in mouse and human islets. These data refine our understanding of GLP-1 pharmacology and identify 14-3-3-zeta as a potential target to enhance α cell GLP-1 production.
AAAS